Advanced Biologics Awarded Supplier Agreement with Premier Healthcare Alliance for OsteoAMP® Product Line

LADERA RANCH, Calif., April 10, 2012 /PRNewswire via COMTEX/ — Advanced Biologics announced today that its OsteoAMP® product platform has been awarded a supplier contract with the Premier Healthcare Alliance. Effective July 1st, 2012, the agreement makes the revolutionary osteobiologic line available to Premier’s 2500+ hospital members.OsteoAMP® is an award-winning allogeneic growth factor that is a lower-cost alternative to recombinant growth factors, such as rhBMP-2 (Infuse®, Medtronic). In a recent head to head clinical study, OsteoAMP® displayed superior fusion rates to rhBMP-2 (Infuse®, Medtronic). With the recent reports of adverse events and complications related to use of rhBMP-2, it has raised many ethical, legal, and reimbursement concerns for surgeons and hospitals. OsteoAMP® represents a new category within the ‘bone, tissue, synthetic implantable product’ market to address such concerns and has already been used in orthopaedic/neurosurgery cases for three years without a single adverse event reported. Additionally, OsteoAMP®’s four distinctive formats (granules, compressible sponges, putty, and structural grafts) provide a distinct advantage by allowing surgeons to tailor deliver the technology according to their needs in surgery.”We are excited to be associated with Premier Healthcare and the opportunity of offering Premier members a truly viable, cost-effective alternative to rhBMP-2,” stated Amit Govil, President of Advanced Biologics. “We will continue to strive in developing products that not only meet or exceed efficacy requirements but also to ensure patient safety.”